Physician profile
Mikhail Regelman
NPI 1891015384
$9,967.63
in general payments reported to CMS, 2019-2025
28 companies · $3,988 in 2025
The $3,988 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2021: $928 · 2022: $1,175 · 2023: $1,468 · 2024: $221 · 2025: $3,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,071 · Travel and Lodging: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,071.11 |
| Travel and Lodging | $605.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,757.75 | 2025 | |
| Genzyme Corporation | $2,188.00 | 2019 | |
| Blue Earth Diagnostics | $933.89 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $502.39 | 2023-2025 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $484.34 | 2022 | |
| Dendreon Pharmaceuticals LLC | $394.17 | 2021-2023 | Provenge |
| Janssen Biotech, INC. | $282.03 | 2022-2025 | Erleada |
| Abbvie INC. | $206.70 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $191.22 | 2022-2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $108.40 | 2022-2025 | Jelmyto |
| Astellas Pharma US INC | $108.32 | 2022-2023 | Myrbetriq |
| Antares Pharma, INC. | $96.26 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Janssen Scientific Affairs, LLC | $94.25 | 2023 | Erleada, Balversa |
| Pfizer INC. | $86.85 | 2023-2024 | |
| Accord Healthcare, INC. | $85.28 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $64.93 | 2024 | Xiaflex, Aveed |
| Amgen INC. | $61.48 | 2022-2023 | Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $59.40 | 2022-2023 | |
| Procept Biorobotics Corporation | $49.42 | 2024-2025 | Aquabeam System |
| Merck Sharp & Dohme LLC | $42.19 | 2021-2023 | Lynparza, Keytruda |
| Davol INC. | $34.24 | 2025 | Arista |
| Tolmar, INC. | $28.45 | 2023 | |
| Coloplast Corp | $24.77 | 2023 | Porges Coloplast |
| Photocure INC | $20.47 | 2023 | Cysview |
| Olympus America INC. | $18.35 | 2022 | |
| Karl Storz Endoscopy-America | $16.75 | 2024 | N.A. |
| C. R. Bard, INC. & Subsidiaries | $14.21 | 2024 | Bard Urinary Drainage Bag |
| 180 Medical, INC. | $13.12 | 2023 | Cure Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Regelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.